HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion
Journal of Experimental Medicine · 02.03.2026 · 223 (3)
DOI: 10.1084/jem.20250777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 12.12.2025. Verfasst von Yongkang Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Armstrong Oxygen Biology Research Center and Institute for Cell Engineering, Johns Hopkins University School of Medicine , Baltimore, MD, USA. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Triple Negative Breast Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Immune Evasion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Armstrong Family Foundation.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the highest rates of recurrence, metastasis, and patient mortality due to the absence of effective therapies. Hypoxia-inducible factor 1 (HIF-1) regulates the expression of thousands of RNAs in TNBC. Here, we demonstrate that transcription of the ISG20 gene, which encodes an RNA exonuclease, is activated by HIF-1 in TNBC cells. ISG20-mediated degradation of RHOBTB3 mRNA increases HIF-1α protein expression and activates NANOG signaling, which increases breast cancer stem cell specification and lung metastasis. ISG20 also degrades STAT1 and IRF1 mRNAs, leading to decreased expression of CXCL10 and impaired recruitment of CD8+ T cells and natural killer cells, thereby promoting breast cancer immune evasion. Silencing ISG20 increases the sensitivity of mouse TNBC cells to anti-PD1 antibody immune checkpoint blockade. Our data suggest that targeting ISG20, in combination with immunotherapy, could be an effective therapeutic strategy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Armstrong Oxygen Biology Research Center and Institute for Cell Engineering, Johns Hopkins University School of Medicine , Baltimore, MD, USA.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, MD, USA.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Johns Hopkins University , Baltimore, MD, USA.
- Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Yongkang Yang, Qiaozhu Zuo, Vijay Ramu, Varen Talwar, Yajing Lyu, Chelsey Chen, Daiana Drehmer, Tina Yi-Ting Huang, Shaima Salman, Dominic Dordai, Yufeng Wang, Emmanuel Datan, Elizabeth E Wicks, Gregg L Semenza
Förderung
- Armstrong Family Foundation
Zitieren
APA
Yang, Y., Zuo, Q., Ramu, V., Talwar, V., Lyu, Y., Chen, C., Drehmer, D., Yi-Ting Huang, T., Salman, S., Dordai, D., Wang, Y., Datan, E., Wicks, E. E., & Semenza, G. L. (2026). HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion. Journal of Experimental Medicine, 223(3). https://doi.org/10.1084/jem.20250777
Vancouver
Yang Y, Zuo Q, Ramu V, Talwar V, Lyu Y, Chen C, et al. HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion. Journal of Experimental Medicine. 2026;223(3). doi:10.1084/jem.20250777
BibTeX
@article{Yang2026,
author = {Yang, Yongkang and Zuo, Qiaozhu and Ramu, Vijay and Talwar, Varen and Lyu, Yajing and Chen, Chelsey and Drehmer, Daiana and Yi-Ting Huang, Tina and Salman, Shaima and Dordai, Dominic and Wang, Yufeng and Datan, Emmanuel and Wicks, Elizabeth E and Semenza, Gregg L},
title = {HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {3},
doi = {10.1084/jem.20250777}
}
EUVIMED